CSL Limited (ASX: CSL) shares dropped more than 12% on Wednesday, falling to a session low of $150.21, as investors reacted to weaker half-year earnings just one day after the surprise CEO exit.
The sell-off briefly pushed CSL to multi-year lows before the share price recovered slightly through the session. Even so, it marks another sharp leg down for a company that was once regarded as untouchable among ASX blue chips.
What CSL reported
CSL delivered total revenue of US$8.3 billion for the half, down 4% in constant currency terms. Underlying NPATA came in at US$1.9 billion, a 7% decline on the prior period. Reported net profit (NPAT) fell 81% to US$401 million, reflecting one-off restructuring costs, and asset impairments of around US$1.1 billion.
The interim dividend was held steady at US$1.30 per share. Cash flow from operations rose 3% to US$1.3 billion. Management also expanded the share buyback from US$500 million to US$750 million.
On paper, reaffirming guidance for the full year should have helped sentiment, but investors clearly wanted more reassurance.
Where the pressure came from
The result was weighed down by government policy changes, restructuring costs and around in impairments, primarily linked to CSL Vifor and Seqirus
Breaking it down by division:
- CSL Behring revenue declined 7%, including softer immunoglobulin sales
- Seqirus revenue fell 2%, partly reflecting non-recurring avian influenza revenue in the prior year
- CSL Vifor grew revenue 12%, driven by nephrology growth
In short, parts of the business are stabilising, but core areas remain under pressure.
When combined with Tuesday’s abrupt CEO transition, the earnings release intensified the perception that CSL is in the middle of a deeper reset rather than a simple cyclical slowdown.
Why the reaction was so sharp
This was not just about a 7% profit decline.
It was about expectations.
CSL has spent years building a reputation as one of Australia’s most reliable compounders. When a company of that stature reports falling revenue, falling underlying profit, significant impairments, and a sudden leadership change within 24 hours, markets tend to react forcefully.
Investors appear to be reassessing what “normal” growth looks like for CSL.
Holding guidance is constructive. However, confidence is not rebuilt by numbers alone. It requires consistent execution over time.
The bigger picture for Raskals
We said in our previous article that no company is too big to fall. Today’s CSL move reinforces that lesson.
CSL remains a global biotechnology leader with strong intellectual property, global plasma infrastructure, and long-term demand drivers. Those foundations have not disappeared.
However, the share price tells us that the market wants clearer proof of operational momentum returning. It wants to see margins improve. And it wants leadership clarity following a turbulent week.
Earnings seasons can be brutal when expectations are high and patience is thin. CSL is now firmly in “prove it” territory.
That does not define the next decade. But it does define the next few reporting periods.
